1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Poland

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Table Of Contents

IMS Pharmaceutical Pricing and Reimbursement Concise Guide: Poland
POLAND 1
HEALTHCARE SYSTEM1
Facts and Figures1
Market Indicators2
Provision and Funding4
Health Insurance4
Primary and Secondary Care6
PRICING6
Prescription Drugs6
Applications7
Price Negotiations7
Listing Agreements9
“Ex-officio” Pricing Procedure9
Generic Drugs10
Hospital Drugs11
Reference Reimbursement Prices11
Tenders11
OTC Drugs11
REIMBURSEMENT12
Admission to Reimbursement12
Applications12
Process14
Decision 15
Listing Agreements16
Reimbursement List17
Timelines17
Appeals17
Drug Programmes18
Chemotherapy Programmes19
Non-reimbursed Drugs20
Reimbursement Categories20
Reimbursement Levels20
Reimbursement Channels21
Reimbursement Prices22
Reference Price Groups22
Reference Prices23
Hospital Reimbursement23
Formularies23
Funding23
Changes in Reimbursement Status24
End of Reimbursement Period24
Expiry of Patent26
Delistings27
Reimbursement List Updates27
Changes in Reimbursement Prices28
Price Increases28
Price Reductions29
Reimbursement Reviews29
Reimbursement List Updates30
PHARMACOECONOMICS 31
Pharmacoeconomic Requirements31
Information Requirements31
Evaluation33
Controversy 35
PRICE BUILD UP35
Wholesalers35
Margins35
Background36
Shortages37
Retail Pharmacies37
Margins37
Background38
Mail-order/E-pharmacy39
Dispensing Doctors39
Sales Tax39
COST CONTAINMENT40
Industry Paybacks40
Promotional Costs41
Expenditure41
Advertising 41
Patient Co-payments41
Pharmaceuticals41
Primary and Secondary Care 43
Prescribing Controls43
Prescribing Regulations43
Monitoring44
Other Controls44
Prescribing Rights45
Generics45
Generic Substitution 45
INN Prescribing45
Pharmacy Margins46
Rx-to-OTC Switches46
Parallel Trade47
Parallel Imports47
Parallel Exports47
FUTURE DEVELOPMENTS48
Outlook 48
Healthcare System48
Hospital Drug Pricing48
Free Medicines for Older Patients49
NAMES and ADDRESSES49

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.